Clinical trials: Pancreatic Cancer Stage III
Pancreatic Cancer
Radiation Therapy Plus Paclitaxel in Treating Patients With Nonmetastatic, Unresectable Pancreatic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003591
- Testing
- paclitaxel, radiation therapy
- Where
- 234 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- Radiation Therapy Oncology Group
Pancreatic Neoplasms
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Primary Objective: To demonstrate that the addition of oxaliplatin to 5-Fluorouracil (5-FU) and Leucovorin (LV) will improve the Progression-Free Survival (PFS).
- Trial name
- NCT01121848
- Testing
- Leucovorin, OXALIPLATIN, 5-Fluorouracil
- Where
- 15 sites in Canada
- Volunteers
- 108 people
- Sponsor
- Sanofi
Pancreatic Cancer, Periampullary Adenocarcinoma
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00983268
- Testing
- capecitabine, vorinostat, Radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy
- Trial name
- ADVANTAGE (NCT06714604)
- Testing
- FOLFIRINOX or gemcitabine-nab-paclitaxel
- Where
- Sweden
- Volunteers
- 432 people
- Sponsor
- Sahlgrenska University Hospital
Pancreatic Cancer
Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Interferon alfa may interfere with the growth of tumor cells.
- Trial name
- NCT00059826
- Testing
- interferon-alfa-2b, cisplatin, 5-fluorouracil
- Where
- 14 sites in United States
- Volunteers
- 89 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
This phase I trial identifies the best dose, possible benefits and/or side effects of gemcitabine in combination with elimusertib (BAY 1895344) in treating patients with pancreatic, ovarian, and other solid tumors that have…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04616534
- Testing
- Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms, Urogenital Neoplasm
The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery
To study if plasma volume expansion is influenced by the rate at which a colloidal solution is administered in patients with a systemic inflammatory response induced by major abdominal surgery.
- Conditions
- Pancreatic Neoplasms, Urogenital Neoplasm, Systemic Inflammatory Response Syndrome, Hypovolemia
- Trial name
- AIR (NCT02728921)
- Testing
- 5% Albumin infusion 30 min, 5% Albumin infusion 3 hours
- Where
- Sweden
- Volunteers
- 70 people
- Sponsor
- Region Skane
Pancreatic Cancer
ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have advanced cancer…
- Trial name
- NCT00005594
- Testing
- ISIS 2503
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01839981
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Pancreatic Cancer
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006467
- Testing
- ISIS 2503, gemcitabine hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Cancer
Glufosfamide With or Without Hydration in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Hydration with a saline solution may protect kidney cells from the side effects of chemotherapy.
- Trial name
- NCT00005053
- Testing
- glufosfamide
- Where
- 15 sites in Denmark, France and 5 more
- Volunteers
- 35 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
Aberrant miRNA production has been linked to a wide range of human cancers and shown to play important roles in their genesis and growth. These miRNA can be detected in the blood and tumors of patients with cancer.
- Conditions
- Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms
- Trial name
- NCT04406831
- Testing
- Blood draw
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Nuvance Health
Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV
Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer
To evaluate the safety and efficacy of non-myeloablative hematopoietic stem cell transplantation in the treatment of pancreatic cancer.
- Trial name
- HST (NCT03236883)
- Testing
- Gemcitabine, GPBSC
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreatic Cancer
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003546
- Testing
- gemcitabine hydrochloride, radiation therapy
- Where
- 48 sites in United States
- Volunteers
- 43 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer, Esophageal Cancer
LMB-9 Immunotoxin in Treating Patients With Advanced Pancreatic, Esophageal, Stomach, Colon, or Rectal Cancer
RATIONALE: LMB-9 immunotoxin can locate tumor cells and kill them without harming normal cells. This may be an effective treatment for advanced pancreatic, esophageal, stomach, colon or rectal cancer.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT00010270
- Testing
- LMB-9 immunotoxin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Freiburg
Lung Cancer, Malignant Mesothelioma
Alanosine in Treating Patients With Cancer
RATIONALE: Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma
- Trial name
- NCT00062283
- Testing
- L-alanosine
- Where
- 12 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have locally…
- Trial name
- NCT00053222
- Testing
- arsenic trioxide
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- University of Chicago
Pancreatic Cancer
A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma
Four-drug combo yielded a statistically significant improvement in progression-free survival and overall survival compared to gemcitabine in patients with advanced pancreatic adenocarcinoma.
- Trial name
- PACT-19 (NCT01730222)
- Testing
- cisplatin, capecitabine, gemcitabine
- Where
- Italy
- Volunteers
- 137 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Neoplasms
Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer
This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countries.
- Trial name
- NCT02043288
- Testing
- NC-6004, Gemcitabine
- Where
- 43 sites in Hong Kong, Japan and 5 more
- Volunteers
- 310 people
- Sponsor
- Orient Europharma Co., Ltd.
Stage IVA Pancreatic Cancer, Stage III Pancreatic Cancer
Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different ways, such as directly into the abdomen, and combining chemotherapy with…
- Conditions
- Stage IVA Pancreatic Cancer, Stage III Pancreatic Cancer, Adenocarcinoma of the Pancreas
- Trial name
- NCT00020345
- Testing
- fluorouracil, gemcitabine
- Where
- 2 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)